DE1216866B - Verfahren zur Herstellung von Carbonsaeureestern des 4-Aminobutin-(2)-ols-(1) und deren therapeutisch vertraeglichen Salzen - Google Patents

Verfahren zur Herstellung von Carbonsaeureestern des 4-Aminobutin-(2)-ols-(1) und deren therapeutisch vertraeglichen Salzen

Info

Publication number
DE1216866B
DE1216866B DEM49737A DEM0049737A DE1216866B DE 1216866 B DE1216866 B DE 1216866B DE M49737 A DEM49737 A DE M49737A DE M0049737 A DEM0049737 A DE M0049737A DE 1216866 B DE1216866 B DE 1216866B
Authority
DE
Germany
Prior art keywords
radical
ester
general formula
acid
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DEM49737A
Other languages
German (de)
English (en)
Inventor
Kenneth N Campbell
Robert F Majewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mead Johnson and Co LLC
Original Assignee
Mead Johnson and Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mead Johnson and Co LLC filed Critical Mead Johnson and Co LLC
Publication of DE1216866B publication Critical patent/DE1216866B/de
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DEM49737A 1960-07-26 1961-07-19 Verfahren zur Herstellung von Carbonsaeureestern des 4-Aminobutin-(2)-ols-(1) und deren therapeutisch vertraeglichen Salzen Pending DE1216866B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4529260A 1960-07-26 1960-07-26
US118261A US3176019A (en) 1960-07-26 1961-06-20 Substituted aminobutynyl acetates

Publications (1)

Publication Number Publication Date
DE1216866B true DE1216866B (de) 1966-05-18

Family

ID=26722613

Family Applications (1)

Application Number Title Priority Date Filing Date
DEM49737A Pending DE1216866B (de) 1960-07-26 1961-07-19 Verfahren zur Herstellung von Carbonsaeureestern des 4-Aminobutin-(2)-ols-(1) und deren therapeutisch vertraeglichen Salzen

Country Status (9)

Country Link
US (1) US3176019A (enExample)
BE (1) BE606560A (enExample)
CH (1) CH421078A (enExample)
DE (1) DE1216866B (enExample)
DK (1) DK113854B (enExample)
ES (1) ES269353A1 (enExample)
FR (1) FR1325M (enExample)
GB (1) GB940540A (enExample)
NL (2) NL124473C (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US3864388A (en) * 1970-12-29 1975-02-04 Sumitomo Chemical Co Alkynyl esters of {60 -alkoxy-{60 -phenyl alkenoic acid
US5036107A (en) * 1986-06-27 1991-07-30 Marion Merrell Dow Inc. 1,7-substituted heptyn-2-ones and use
US4957941A (en) * 1987-11-16 1990-09-18 United Pharmaceuticals, Inc. Anti-spasmdoic agents having an acetylenic bond
IL91377A (en) * 1988-09-14 1996-09-12 Nippon Shinyaku Co Ltd Derivatives of botinylamine glycolate
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
WO1998001125A2 (en) * 1996-07-09 1998-01-15 Sepracor, Inc. Dextrorotatory isomers of oxybutynin and desethyloxybutynin in the treatment of gastrointestinal hyperactivity
US6140529A (en) * 1998-10-22 2000-10-31 Sepracor Inc. Synthesis of optically active cyclohexylphenylglycolate esters
US5973182A (en) * 1998-10-22 1999-10-26 Sepracor Inc. Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters
CN1438861A (zh) * 2000-04-26 2003-08-27 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
ATE418534T1 (de) 2001-10-26 2009-01-15 Pharmacia & Upjohn Co Llc Quaternäre ammoniumverbindungen und deren verwendung als antimuscarinische wirkstoffe
NZ537584A (en) 2002-07-08 2006-07-28 Ranbaxy Lab Ltd 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
WO2004014853A1 (en) * 2002-07-31 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
AU2002321711A1 (en) * 2002-08-09 2004-02-25 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives useful as muscarinic receptor antagonist
JP2006501236A (ja) * 2002-08-23 2006-01-12 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有3,6−二置換アザビシクロ(3.1.0)ヘキサン誘導体
TW200412945A (en) 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
AU2002347552A1 (en) * 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2002347553A1 (en) * 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CA2521788A1 (en) * 2003-04-10 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003223010A1 (en) 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) * 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
EP1765809B1 (en) * 2004-06-16 2008-12-31 Ranbaxy Laboratories Limited Xanthine derivatives useful as muscarinic receptor antagonists
EP1781607A2 (en) * 2004-08-19 2007-05-09 Ranbaxy Laboratories Limited Pyrrolidine derivatives as muscarinic receptor antagonists
WO2006032994A2 (en) * 2004-09-24 2006-03-30 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2006035303A1 (en) * 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2006054162A1 (en) * 2004-11-19 2006-05-26 Ranbaxy Laboratories Limited Azabicyclic muscarinic receptor antagonists
WO2006064304A1 (en) * 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
EP1888525A1 (en) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
US20090010923A1 (en) * 2007-04-24 2009-01-08 University Of Maryland, Baltimore Treatment of cancer with anti-muscarinic receptor agents
WO2009122429A2 (en) * 2008-02-04 2009-10-08 Matrix Laboratories Limited Crystalline oxybutynin and process for preparing the same
AU2011245499B2 (en) 2010-04-30 2014-09-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US8642661B2 (en) 2010-08-03 2014-02-04 Altherx, Inc. Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
KR20150020160A (ko) 2012-02-09 2015-02-25 앨씨알엑스, 인크. 과민성 방광의 치료를 위한 무스카린 수용체 길항제 및 베타―3 아드레날린 수용체 작용제의 조합물
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
HRP20241412T1 (hr) 2018-01-30 2024-12-20 Apnimed, Inc. (Delaware) Postupci i pripravci namijenjeni liječenju apneje u snu ili običnog hrkanja
CR20220617A (es) 2020-05-05 2023-02-09 Apnimed Inc Formas polimórficas de clorhidrato de (r)-oxibutinina

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE895595C (de) * 1943-09-29 1953-11-05 Basf Ag Verfahren zur Herstellung von Aminoalkinolen
DE1003209B (de) * 1953-03-24 1957-02-28 Basf Ag Verfahren zur Herstellung spasmolytisch wirksamer basischer Carbinole
DE1083254B (de) * 1957-04-01 1960-06-15 Lakeside Lab In Verfahren zur Herstellung von blutdrucksenkenden N-disubstituierten Diaminoalkinen, deren Saeureadditionssalzen oder quaternaeren Ammoniumsalzen
DE1100617B (de) * 1959-10-22 1961-03-02 Basf Ag Verfahren zur Herstellung von 1-Dialkylamino-4-hydroxy-acetylenen-(2)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2867619A (en) * 1956-11-05 1959-01-06 Lakeside Lab Inc Aminoalkynyl-n-alkylpiperidine carboxylates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE895595C (de) * 1943-09-29 1953-11-05 Basf Ag Verfahren zur Herstellung von Aminoalkinolen
DE1003209B (de) * 1953-03-24 1957-02-28 Basf Ag Verfahren zur Herstellung spasmolytisch wirksamer basischer Carbinole
DE1083254B (de) * 1957-04-01 1960-06-15 Lakeside Lab In Verfahren zur Herstellung von blutdrucksenkenden N-disubstituierten Diaminoalkinen, deren Saeureadditionssalzen oder quaternaeren Ammoniumsalzen
DE1100617B (de) * 1959-10-22 1961-03-02 Basf Ag Verfahren zur Herstellung von 1-Dialkylamino-4-hydroxy-acetylenen-(2)

Also Published As

Publication number Publication date
CH421078A (de) 1966-09-30
GB940540A (en) 1963-10-30
FR1325M (fr) 1962-05-21
NL124473C (enExample)
US3176019A (en) 1965-03-30
BE606560A (fr) 1962-01-26
DK113854B (da) 1969-05-05
ES269353A1 (es) 1961-11-16
NL267508A (enExample)

Similar Documents

Publication Publication Date Title
CH421078A (de) Verfahren zur Herstellung von Aminoacetylenverbindungen
DE1518452C3 (de) 4 substituierte 2 Benzhydryl 2 butanol Derivate und Verfahren zu ihrer Herstellung
EP0110869A1 (de) Thienylessigsäureamidderivate und pharmazeutisch verträgliche Säureadditionssalze hiervon sowie Verfahren zu deren Herstellung
DE2617955A1 (de) Neue l-substituierte -aroyl-4-hydroxypiperidine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
EP0018360B1 (de) N-(5-Methoxybentofuran-2-ylcarbonyl)-N'-benzylpiperazin und Verfahren zu dessen Herstellung
DE2315148A1 (de) Neue chinolinderivate, verfahren zu ihrer herstellung und ihre verwendung
DE1001261C2 (de) Verfahren zur Herstellung von basischen Estern endocyclisch substituierter Mandelsaeuren und ihren Salzen
DE2155406C3 (de) 3- eckige Klammer auf 2-(3-Bromphenyl)-5-tetrazolyl eckige Klammer zu -propionsäureamide
DE1620325C3 (de) Disubstituierte Isoxazolverbindungen
DE2541932A1 (de) Piperidinderivate, verfahren zu ihrer herstellung und sie enthaltendes pharmazeutisches mittel
DE2560602C2 (de) Sauerstoffhaltige Diarylamidine
DE2903917C2 (enExample)
DE1289050B (de) Verfahren zur Herstellung von 3-(3'-Hydroxyphenyl)-1-phenacyl-piperidinen
AT242137B (de) Verfahren zur Herstellung von neuen Derivaten des 4-Aminobutin-(2, 3)-ols-1 und deren Salzen
DE949232C (de) Verfahren zur Herstellung therapeutisch wertvoller basischer substituierter Essigsaeureester
DE2523208C3 (de) Thienylessigsäureester, ein Verfahren zu ihrer Herstellung sowie Arzneimittel
DE2423725A1 (de) 5-phenyl-4-oxo-delta hoch 2,alphathiazolidinessigsaeureester
DE1695707C3 (de) Benzimidazolderivate und Verfahren zu ihrer Herstellung
AT256834B (de) Verfahren zur Herstellung von neuen Aminoalkyl-substituierten 5-gliedrigen Heterocyclen und ihren Salzen
DE1593711C3 (de) Verfahren zur Herstellung von alpha-Cycloalkylderivaten von alpha-Amino-propionyl-o-toluidid bzw. deren Salzen
DE1018868B (de) Verfahren zur Herstellung von Phenthiazinderivaten
DE1620206C (de) N-Cyclopropylmethyl-6,14-endo-äthanotetrahydronororipavine und ihre Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
AT267075B (de) Verfahren zur Herstellung von neuen, am Stickstoff substituierten 3-(Dibenzo-[a,d]-1,4-cycloheptadien-5-yloxy)-nortropanen und von Salzen dieser Verbindungen
AT356665B (de) Verfahren zum herstellen neuer chinuclidin- derivate, ihren stereoisomeren, optischen isomeren und salzen
DE1235310B (de) Verfahren zur Herstellung von Nopinsaeurederivaten